Highlights

  • PainChek (ASX:PCK) is building a US commercial presence following FDA De Novo clearance for its PainChek Adult app.
  • The company has secured early US customers and a broader deployment pathway through Sabra Health Care REIT.
  • New CEO Karen Holzberger brings extensive US healthcare technology experience to the next phase of commercialisation.
  • Expansion into the US offers a significant growth opportunity, but execution, funding and adoption risks remain important.

PainChek (ASX:PCK) has spent the past year turning a single US regulatory breakthrough into a commercial foothold in the world's largest healthcare market. In August 2026, the ASX-listed MedTech appointed Karen Holzberger — a 26-year healthcare technology veteran who most recently led US medical-imaging company SpinTech MRI — as its new chief executive, a hire built around one goal: converting the company's 2025 FDA clearance into recurring US revenue.

Investors are now waiting to see whether an AI tool that reads facial expressions, vocalisations and body movement to detect pain in people who cannot verbally communicate can scale beyond pilot deployments. Early signs — a multi-year deal anchored by a Nasdaq-listed aged-care landlord and a first paying US customer — suggest the shift from technology story to commercial story is under way.

What Has Happened?

The pivotal event was PainChek receiving FDA De Novo classification for its PainChek Adult app on 8 October 2025, establishing a new product code and recognising it as a first-of-its-kind medical device for assessing pain in people with moderate to severe dementia.

The clearance opened access to a US long-term care market covering more than three million beds and was quickly followed by commercial traction. Jewish Home Family, a New Jersey senior-care organisation, signed a three-year agreement shortly after clearance, becoming PainChek's first US customer.

The company then landed a considerably larger relationship with Sabra Health Care REIT, a Nasdaq-listed owner of aged-care facilities, under a Master Services Agreement that can extend to as many as 20,000 beds. PainChek flagged a "landmark Sabra North America deployment" in April 2026 and confirmed in June 2026 that initial Sabra facilities had gone live. To help fund the US push, PainChek raised an A$5.5 million note in May 2026.

Leadership has also been in flux. The board announced a CEO transition in July 2026, with interim Leadership under Andy Hoggan before Karen Holzberger's appointment took effect on 17 August 2026; Hoggan reverts to his prior Chief Operating Officer role. Lil Bianchi was separately appointed Non-Executive Chair in May 2026, and the company reported a $1.123 million tax refund in July 2026 and "material sales momentum" in the UK in March 2026.

Understanding the Business

PainChek (ASX:PCK) develops a smartphone- and tablet-based application that combines AI-enabled facial recognition with a clinician-observed checklist to assess pain in people who cannot reliably self-report it — principally dementia patients, but also infants and people with intellectual disabilities or in palliative care.

The suite spans PainChek Adult, Infant and Universal, first commercialised across Australian and UK aged-care and disability providers.

Its go-to-market model is subscription-based, priced per Facility or bed, and increasingly reliant on integration with electronic health-record systems already used by aged-care operators, including PointClickCare and Eldermark in the US. Rather than selling PainChek as a standalone app, the company is embedding it into workflows operators already use, lowering the barrier to adoption at scale.

Financial and Operational Picture

PainChek reports its financial position through quarterly Appendix 4C cash-flow statements, including updates for the periods ended 30 January, 30 April and 30 June 2026.

The company has continued to rely on external funding to support its expansion, notably the A$5.5 million note secured in May 2026, alongside the $1.123 million tax refund received in July 2026 that provided a non-dilutive top-up to cash resources.

Specific US Revenue contribution from the Jewish Home Family and Sabra relationships has not yet been broken out in company disclosures reviewed for this article, so no figures are presented here beyond what has been confirmed. What is clear is that UK trading showed "material sales momentum" as at March 2026, suggesting the established ANZ and UK businesses continue to underpin the group while the US operation is built out from a low base.

Why This Matters

Bringing in a chief executive with direct experience commercialising an FDA-cleared device in the US — rather than another clinical or regulatory specialist — signals that PainChek's board sees the next phase as one of sales execution rather than further validation.

The FDA clearance itself, covering an addressable market of more than three million long-term care beds, combined with an anchor relationship at a listed REIT landlord with a footprint of up to 20,000 beds, gives the company a credible distribution pathway that simply did not exist before October 2025.

For a company of PainChek's size, landing even a modest share of that opportunity would represent a meaningful increase in scale relative to its existing ANZ and UK operations.

Industry Opportunity

Global population ageing and rising dementia prevalence are well-documented tailwinds for aged-care technology, and pain under-detection in non-verbal patients is a recognised clinical gap that digital tools are increasingly asked to close.

In the US, long-term care is dominated by large operators and real-estate Investment trusts, meaning a single anchor relationship such as the one with Sabra can open a wide distribution funnel across many facilities rather than requiring PainChek to win each site independently.

More broadly, aged-care providers globally face regulatory and workforce pressure to demonstrate better clinical outcomes with fewer staff, a dynamic that favours AI-assisted assessment tools deployable without adding headcount.

Potential Catalysts

Investors may be watching for expansion of live, paying beds under the Sabra agreement beyond the initial facilities confirmed in June 2026, toward the broader 20,000-bed ceiling.

Additional US customers beyond Jewish Home Family, conversion of the PointClickCare and Eldermark integrations into paid deployments, and Holzberger's first substantive commercial update are plausible near-term catalysts, as is continued UK and ANZ momentum supporting the US build-out.

Risks Investors Should Consider

Enterprise sales cycles in aged care are typically long, and a signed Master Services Agreement covering many beds does not guarantee the pace at which facilities go live and generate revenue.

PainChek's use of debt-like instruments, such as the A$5.5 million note, points to an ongoing need for capital, and a funding shortfall or slower-than-expected uptake could necessitate further raisings on less favourable terms.

The company has also had several individuals in senior leadership roles within roughly a year, a reminder that leadership transitions carry execution risk when continuity matters most. Currency exposure from a growing US dollar revenue base reported in Australian dollars, and competitive or reimbursement-related uncertainty in US healthcare technology, are additional factors to weigh.

What to Watch Next

The next Appendix 4C quarterly cash-flow report should provide an updated read on financial resources and any further detail on bed rollout progress under the Sabra agreement.

Beyond that, investors may look for confirmation of new US customer wins beyond Jewish Home Family, further integration milestones with PointClickCare or Eldermark, and Karen Holzberger's initial strategic commentary as she settles into the CEO role.